COMP <GO>
BIIB vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Biogen Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BIIB 6
— ABBV 8
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: BIIB
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
options-implied-move
7.20%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 70.20% | +5.50 | BIIB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 29.00% | -22.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.3x | 33.3x | -11.00 | BIIB | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 3.47% | +2.09 | BIIB | /fcf-yield <GO> |
| Operating Margin | 15.90% | 24.60% | -8.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 6.90% | +6.20 | BIIB | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 8.60% | -6.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 5.33 | -1.63 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.40% | -0.20 | BIIB | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 72.8 | -6.13 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 113.1x | -86.60 | BIIB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $513.86B | -$476.96B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | ABBV REV | BIIB GROSS % | ABBV GROSS % | BIIB FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $61.16B | 75.7% | 70.2% | $2.05B | $17.82B |
| FY 2024 | $9.68B | $56.33B | 76.1% | 70.0% | $2.72B | $17.83B |
| FY 2023 | $9.84B | $54.32B | 44.0% | 44.0% | $1.10B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
ABBV // BETA 1.15